"Fortunately, only a few % of prostate cancer patients die of prostate cancer."
Yes, very true, but it's important to note that there are at least two different things called "prostate cancer":
1. The slow-developing, "you'll probably die of old age before it gets you" type that typically hits in your late 60s, 70s, or 80s. This is what most people think of.
2. The fast-developing type that typically hits in your 40s, 50s, and early 60s, the one that killed people like Johnny Ramone and Frank Zappa long before their time.
The second type used to have a very high mortality rate (and very quickly). It's just in the past few years that we've come up with effective treatments to keep it under control and extend life. It's still often not discovered until it's already at stage 4.
So it's the over-generalisations about prostate cancer, as much as anything else, that kills people: for example, many doctors and agencies recommending stopped PSA screening because of the first type, and the death rate shot up for the second.
Fortunately, these days they're getting better and better at telling the two types apart, so that they don't overtreat the first type (active surveillance is often fine, at least for many years), or undertreat the second (which can metastasise, literally, in months).
All good reasons for early and annual testing, leading to early detection, and then (if needed) taking advantage of the many diagnostic methods, and then (if necessary) taking advantage of the many treatment methods.
Even with Ramone and Zappa (and the many dozens of other celebrities with this disease), had they caught it early enough, the outcome might have been different (or at least not died so soon). And with today’s isotope therapies, immunotherapies, and/or PARP inhibitor therapies, we have tools that they didn’t have back then.
Yes, with the unfortunate decision by the USPSTF in 2012 not to recommend regular PSA screening, more advanced cases went undetected. (I still requested getting annual PSA screening back then. It was in 2012 that we detected my prostate cancer; I was on active surveillance for 9 years before getting active treatment in 2021.)
Fortunately with today’s biomarker (genomic), genetic (germline), and other tracking and testing methods, they can often differentiate the less serious prostate cancers from the more serious prostate cancers, and potentially have more positive outcomes.